Back to all use cases

Build Target Account Lists

Create prioritized lists of pharmaceutical companies for business development outreach.

Prompt

Build me a target account list of top 50 pharma companies ranked by oncology pipeline strength, recent deal activity in biologics, and geographic presence in US/EU. Include key contact roles.

Sample Copilot Response

117s $0.34

Generated a prioritized target account list of pharmaceutical companies based on oncology pipeline strength, recent biologics deal activity, and US/EU geographic presence.

Tier 1: Global Oncology Leaders

Companies with the strongest combination of pipeline depth, major recent deals, and established US/EU operations:

- **Novartis** - Acquired Mariana Oncology for $1B+ (radioligand therapy portfolio)

  • <strong>AbbVie:</strong> - $10.1B acquisition of ImmunoGen (antibody-drug conjugates)
  • <strong>Bristol-Myers Squibb:</strong> - $4.8B purchase of Mirati Therapeutics (PRMT5 inhibitor)
  • <strong>Merck KGaA:</strong> - Advanced talks to acquire SpringWorks Therapeutics (rare cancers)
  • <strong>Sanofi:</strong> - €1.1B bioproduction expansion in France (monoclonal antibodies)

Tier 2: High-Volume Trade Leaders

Companies demonstrating extensive international reach with significant US/EU presence:

- **Dr. Reddy's Laboratories** - $5.96B trade value, 74 countries including extensive US/EU reach

  • <strong>Cipla Limited:</strong> - $171M trade value, 156 countries with strong US/EU presence
  • <strong>Aurobindo Pharma:</strong> - $169M trade value, 153 countries including US/EU markets
  • <strong>Lupin Limited:</strong> - $243M trade value, 131 countries with US/EU operations
  • <strong>Sun Pharmaceutical:</strong> - $113M trade value, 114 countries including US/EU

Tier 3: Specialized Biologics Companies

Emerging players with focused biologics capabilities and growing US/EU footprint:

- **Enzene Biosciences** - $154M trade value, focused biologics with US/EU presence

  • <strong>Mylan Laboratories:</strong> - $114M trade value, 170 countries including strong US/EU
  • <strong>Glenmark Pharmaceuticals:</strong> - $92M trade value, 99 countries with US/EU reach
  • <strong>Intas Pharmaceuticals:</strong> - $72M trade value, 106 countries including US/EU
  • <strong>Emcure Pharmaceuticals:</strong> - $65M trade value, 131 countries with US/EU presence

Key Contact Roles to Target

- Chief Business Development Officer

  • VP of Strategic Partnerships
  • Head of Oncology Business Unit
  • Director of Biologics Development
  • VP of International Markets (US/EU)
  • Head of M&A and Licensing
  • Chief Medical Officer (Oncology)
  • VP of Commercial Operations (US/EU)

Learn more

Effective business development starts with the right target list. PharmaDB helps you identify and prioritize pharmaceutical companies based on strategic fit, deal-making appetite, and organizational readiness—ensuring your BD team focuses on the highest-value opportunities.

Key benefits:

  • Build account lists using multi-dimensional filtering and scoring
  • Prioritize targets based on strategic alignment and deal likelihood
  • Track account engagement and relationship history
  • Generate custom reports for BD team outreach

Perfect for: Business development teams, corporate development professionals, and alliance managers prospecting for partnerships.

Build smarter target lists

Strategic fit scoring

Rank companies based on:

  • Therapeutic area alignment - Pipeline focus matching your assets
  • Development stage preferences - Historical deal patterns by phase
  • Geographic strategy - Market presence in target regions
  • Technology platforms - Capability gaps your asset could fill
  • Financial capacity - Recent funding, cash position, deal budget

Deal readiness indicators

Prioritize accounts showing:

  • Recent deal activity - Frequency and recency of partnerships
  • Partnership patterns - Preferred deal structures and terms
  • Pipeline gaps - Therapeutic areas with thin coverage
  • Strategic pivots - M&A activity or portfolio refocusing
  • Management changes - New BD leadership or strategy shifts

Contact intelligence

For each target, access:

  • Decision maker profiles - BD leads, therapeutic area heads, C-suite
  • Organizational structure - Reporting lines and approval processes
  • Contact history - Previous interactions and engagement touchpoints
  • Network connections - Shared advisors, board members, investors

Optimize BD workflow

Smart segmentation

Organize targets into tiers:

  • Tier 1 - High strategic fit, active deal makers, strong contact relationships
  • Tier 2 - Good alignment, moderate deal activity, need relationship building
  • Tier 3 - Potential fit, limited data, exploratory outreach

Automated enrichment

PharmaDB continuously updates account intelligence:

  • Pipeline milestones and clinical results
  • Partnership announcements and deal terms
  • Financial updates and earnings calls
  • Leadership changes and strategic pivots

Performance tracking

Monitor BD effectiveness:

  • Outreach response rates by tier
  • Meeting conversion and follow-up activity
  • Pipeline progression from initial contact to term sheet
  • Deal close rates and time to signature

Real-world impact

BD teams using PharmaDB report:

  • 60% more efficient targeting with higher response rates
  • 2x more meetings with strategically aligned companies
  • Faster deal cycles with better-prepared outreach
  • Higher close rates from improved target prioritization